Osteoclast derivation from mouse bone marrow.

Osteoclasts are highly specialized cells that are derived from the monocyte/macrophage lineage of the bone marrow. Their unique ability to resorb both the organic and inorganic matrices of bone means that they play a key role in regulating skeletal remodeling. Together, osteoblasts and osteoclasts are responsible for the dynamic coupling process that involves both bone resorption and bone formation acting together to maintain the normal skeleton during health and disease. As the principal bone-resorbing cell in the body, changes in osteoclast differentiation or function can result in profound effects in the body. Diseases associated with altered osteoclast function can range in severity from lethal neonatal disease due to failure to form a marrow space for hematopoiesis, to more commonly observed pathologies such as osteoporosis, in which excessive osteoclastic bone resorption predisposes to fracture formation. An ability to isolate osteoclasts in high numbers in vitro has allowed for significant advances in the understanding of the bone remodeling cycle and has paved the way for the discovery of novel therapeutic strategies that combat these diseases. Here, we describe a protocol to isolate and cultivate osteoclasts from mouse bone marrow that will yield large numbers of osteoclasts.

[1]  Hua Zhou,et al.  Increased IL‐6 Expression in Osteoclasts Is Necessary But Not Sufficient for the Development of Paget's Disease of Bone , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  T. Martin,et al.  Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. , 2014, BoneKEy reports.

[3]  J. David,et al.  Differential Roles of MAPK Kinases MKK3 and MKK6 in Osteoclastogenesis and Bone Loss , 2014, PloS one.

[4]  M. Almeida,et al.  The role of estrogen and androgen receptors in bone health and disease , 2013, Nature Reviews Endocrinology.

[5]  H. Fiebig,et al.  Intratibial Injection of Human Multiple Myeloma Cells in NOD/SCID IL-2Rγ(Null) Mice Mimics Human Myeloma and Serves as a Valuable Tool for the Development of Anticancer Strategies , 2013, PloS one.

[6]  E. Keller,et al.  Understanding and targeting osteoclastic activity in prostate cancer bone metastases. , 2013, Current molecular medicine.

[7]  I. Roato Interaction among Cells of Bone, Immune System, and Solid Tumors Leads to Bone Metastases , 2013, Clinical & developmental immunology.

[8]  M. Sabbieti,et al.  Endocrine disruptors and bone metabolism , 2013, Archives of Toxicology.

[9]  M. Morris,et al.  Targeting bone physiology for the treatment of metastatic prostate cancer. , 2013, Clinical advances in hematology & oncology : H&O.

[10]  S. Wallet,et al.  Hyperglycemia induced and intrinsic alterations in type 2 diabetes-derived osteoclast function. , 2012, Oral diseases.

[11]  P. Kostenuik,et al.  Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab , 2012, Nature Reviews Drug Discovery.

[12]  Janet E Brown,et al.  Denosumab in patients with cancer—a surgical strike against the osteoclast , 2012, Nature Reviews Clinical Oncology.

[13]  B. Porse,et al.  Bone Marrow-Derived Macrophages (BMM): Isolation and Applications. , 2008, CSH protocols.

[14]  P. Chambon,et al.  Estrogen Prevents Bone Loss via Estrogen Receptor α and Induction of Fas Ligand in Osteoclasts , 2007, Cell.

[15]  K. Takaoka,et al.  Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand. , 2006, Endocrinology.

[16]  S. Teitelbaum,et al.  Genetic regulation of osteoclast development and function , 2003, Nature Reviews Genetics.

[17]  S. Khosla,et al.  Minireview: the OPG/RANKL/RANK system. , 2001, Endocrinology.

[18]  L. Hofbauer,et al.  Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology , 2001, Journal of Molecular Medicine.

[19]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[20]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  T. Martin,et al.  Hormonal Regulation of Osteoclast Function , 1998, Trends in Endocrinology & Metabolism.

[22]  J. Underwood From where comes the osteoclast? , 1984, The Journal of pathology.

[23]  E H Burger,et al.  In vitro formation of osteoclasts from long-term cultures of bone marrow mononuclear phagocytes , 1982, The Journal of experimental medicine.

[24]  D. G. Walker Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells , 1975, Science.

[25]  D. Simmons,et al.  Investigation of cell lineage in bone using a chimaera of chick and quail embryonic tissue , 1975, Nature.

[26]  L. Xing,et al.  RANKL-based osteoclastogenic assays from murine bone marrow cells. , 2014, Methods in molecular biology.